US 11,833,193 B2
A*03 restricted peptides for use in immunotherapy against cancers and related methods
Colette Song, Ostfildern (DE); Linus Backert, Tuebingen (DE); Heiko Schuster, Tuebingen (DE); Daniel Johannes Kowalewski, Kirchentellinsfurt (DE); Oliver Schoor, Tuebingen (DE); Jens Fritsche, Dusslingen (DE); Toni Weinschenk, Aichwald (DE); and Harpreet Singh, Munich (DE)
Assigned to IMMATICS BIOTECHNOLOGIES GMBH, Tuebingen (DE)
Filed by Immatics Biotechnologies GmbH, Tuebingen (DE)
Filed on Jan. 14, 2021, as Appl. No. 17/149,241.
Application 17/149,241 is a continuation of application No. 16/030,725, filed on Jul. 9, 2018, granted, now 10,925,947.
Claims priority of provisional application 62/692,348, filed on Jun. 29, 2018.
Claims priority of application No. 102018115865.3 (DE), filed on Jun. 29, 2018; and application No. 102018116584.6 (DE), filed on Jul. 9, 2018.
Prior Publication US 2021/0138052 A1, May 13, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/00 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 7/06 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01)
CPC A61K 39/0011 (2013.01) [A61P 35/00 (2018.01); C07K 7/06 (2013.01); C07K 16/2833 (2013.01); C07K 16/30 (2013.01); A61K 2039/5158 (2013.01); C07K 2317/32 (2013.01)] 20 Claims
 
1. A peptide consisting of the amino acid sequence of LLDAEPPILY (SEQ ID NO: 32) in the form of pharmaceutically acceptable salt.